DE69125394D1 - Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth) - Google Patents

Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)

Info

Publication number
DE69125394D1
DE69125394D1 DE69125394T DE69125394T DE69125394D1 DE 69125394 D1 DE69125394 D1 DE 69125394D1 DE 69125394 T DE69125394 T DE 69125394T DE 69125394 T DE69125394 T DE 69125394T DE 69125394 D1 DE69125394 D1 DE 69125394D1
Authority
DE
Germany
Prior art keywords
osteoporosis
grf
pth
growth hormone
releasing factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69125394T
Other languages
English (en)
Other versions
DE69125394T2 (de
Inventor
Robert R Recker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GRF CORP., LINCOLN, NEBR., US
Original Assignee
Robert R Recker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert R Recker filed Critical Robert R Recker
Publication of DE69125394D1 publication Critical patent/DE69125394D1/de
Application granted granted Critical
Publication of DE69125394T2 publication Critical patent/DE69125394T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69125394T 1990-11-26 1991-11-01 Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth) Expired - Fee Related DE69125394T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61754390A 1990-11-26 1990-11-26
PCT/US1991/008106 WO1992009304A1 (en) 1990-11-26 1991-11-01 Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)

Publications (2)

Publication Number Publication Date
DE69125394D1 true DE69125394D1 (de) 1997-04-30
DE69125394T2 DE69125394T2 (de) 1997-08-21

Family

ID=24474060

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69125394T Expired - Fee Related DE69125394T2 (de) 1990-11-26 1991-11-01 Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)

Country Status (13)

Country Link
US (1) US5164368A (de)
EP (1) EP0559751B1 (de)
JP (1) JP2557779B2 (de)
AT (1) ATE150648T1 (de)
AU (1) AU645874B2 (de)
CA (1) CA2096350C (de)
DE (1) DE69125394T2 (de)
DK (1) DK0559751T3 (de)
ES (1) ES2099245T3 (de)
FI (1) FI106776B (de)
IE (1) IE913858A1 (de)
NZ (1) NZ240482A (de)
WO (1) WO1992009304A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5492920A (en) * 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
SK56296A3 (en) * 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
US5700775A (en) * 1995-03-24 1997-12-23 Gutniak; Mark K. Method and treatment composition for decreasing patient time in catabolic state after traumatic injury
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
US5869041A (en) * 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
JP2000512274A (ja) * 1996-05-31 2000-09-19 ノボ ノルディスク アクティ―ゼルスカブ 骨粗しょう症の周期的（整合性）治療における成長ホルモン成分及び骨抗吸収剤
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
AU2002300896B2 (en) * 1997-06-19 2006-03-30 Nps Pharmaceuticals, Inc. Method of enhancing bone mineral density
WO1999006563A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
EP1119251A4 (de) * 1998-10-07 2004-03-24 Univ Arkansas Verfahren für das screening auf wirkstoffe für die anabole knochentherapie, die die apoptosis kontrollieren, und ihre verwendung
US6416737B1 (en) 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
US7994129B2 (en) * 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
AR079234A1 (es) 2009-12-01 2012-01-04 Abbott Lab Derivados heterociclicos condensados nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar afecciones oncologicas, del sistema nervioso y/o del sistema inmune.
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870094A (en) * 1984-05-02 1989-09-26 Uniroyal Chemical Company, Inc. Substituted imidazoles and triazoles
US4870054A (en) * 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
US4710382A (en) * 1985-09-27 1987-12-01 Recker Robert R Treatment for osteoporosis using hGRF(1-40)NH2
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4833123A (en) * 1987-10-08 1989-05-23 Sumitomo Chemical Company Limited Yellow dye-donor element used in thermal transfer and thermal transfer and thermal transfer sheet using it
WO1989007113A1 (en) * 1988-01-29 1989-08-10 The Upjohn Company Grf analogs

Also Published As

Publication number Publication date
DK0559751T3 (da) 1997-10-06
FI106776B (fi) 2001-04-12
EP0559751B1 (de) 1997-03-26
CA2096350C (en) 2001-10-16
EP0559751A4 (en) 1994-07-13
ATE150648T1 (de) 1997-04-15
JP2557779B2 (ja) 1996-11-27
AU645874B2 (en) 1994-01-27
US5164368A (en) 1992-11-17
JPH06502863A (ja) 1994-03-31
CA2096350A1 (en) 1992-05-27
AU9073591A (en) 1992-06-25
IE913858A1 (en) 1992-06-03
FI932385A0 (fi) 1993-05-26
NZ240482A (en) 1997-06-24
EP0559751A1 (de) 1993-09-15
DE69125394T2 (de) 1997-08-21
FI932385A (fi) 1993-05-26
ES2099245T3 (es) 1997-05-16
WO1992009304A1 (en) 1992-06-11

Similar Documents

Publication Publication Date Title
DE69125394T2 (de) Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)
RU2224539C2 (ru) Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр)
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
DE3866817D1 (de) Knochenzement zur kontrollierten abgabe von wirkstoffen.
CA2124792A1 (en) Methods for the Treatment of Osteoporosis Using Bisphosphonates and Parathyroid Hormone
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
RU95110107A (ru) Способ получения стабильного кристаллического аналога цинк-инсулина
FI952701A0 (fi) Metallisen kirurgisen istukkaan käsittelymenetelmä
DE69113470D1 (de) Intraokulares und intraorbitales Implantat zur kontrollierten Zuführung von Arzneimitteln.
YU46794A (sh) Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena
CA2032123A1 (fr) Dispositif de renfort et de soutien de la coiffe des rotateurs d'une articulation d'epaule d'individus
DK0725648T3 (da) Leverspecifikke farmaceutiske aktivstoffer
DK336986A (da) Fremgangsmaade til fremstilling af taerre biologisk aktive rekombinante vaeksthormoner
ATE208612T1 (de) Biologisch erodierbare vorrichtung zur verabreichung von wirkstoffen
DE59009462D1 (de) Implantierbare Vorrichtung zur dosierten Abgabe von Medikamenten in den menschlichen Körper.
SE8405596D0 (sv) A method of producing a mono- or multilayered prothesis material and the material hereby obtained
IL99732A0 (en) Vascularization promoting implant material
BG100517A (en) Combination of bisphosphonates and growth hormone secretagogues
IL100585A0 (en) Use of human igf-i
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
RU93005051A (ru) Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации
GEP20033095B (en) Parathyroid Hormone Analogues for the Treatment of Osteoporosis
ATE447410T1 (de) Verwendung von humanem parathyroid-hormon
FR2655276B1 (fr) Microemulsions concentrees de matieres organiques diluables sous forme d'emulsions stables et leur procede de preparation.
DE69316013T2 (de) Verwendung von phosphinate zur behandlung der osteoporose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GRF CORP., LINCOLN, NEBR., US

8328 Change in the person/name/address of the agent

Representative=s name: FUCHS, MEHLER, WEISS & FRITZSCHE, 81545 MUENCHEN

8381 Inventor (new situation)

Inventor name: RECKER, ROBERT R., OMAHA, NEBR., US

8339 Ceased/non-payment of the annual fee